Webinar | Intra-Aortic Balloon Pumps (IABP)| December 22, 2015

Webinar: Hemodynamics of Counterpulsation

This webinar is sponsored by Maquet

IABP

The webinar "Hemodynamics of Counterpulsation" explained how the intra-aortic balloon pump (IABP) can increase diastolic aortic pressure and augment coronary blood flow and reduce aortic and left ventricular systolic pressure or afterload. This education offering provides a review of the physiologic benefits, evaluation of patient response, discusses how patients may derive the most benefit and offers practical technical components to optimize IABP therapy.


The live webinar was Jan. 28, 2016, but a recorded version is available on demand.  
Register for the on demand webinar


Statement of Purpose/Need: 

The Intra-aortic balloon pump (IABP) has been the first-line choice for mechanical circulatory support around the world due to its clinical efficacy, safety profile across a broad range of patient care scenarios, and low cost. IABP therapy is the most widely used nondurable mechanical circulatory support device (MCS), with more than 160,000 IAB catheters placed globally per a year. The primary goals of the IABP are to (1) increase diastolic aortic pressure and augment coronary blood flow, and (2) reduce aortic and left ventricular systolic pressure or afterload. This education offering will provide a review of the physiologic benefits, evaluate patient response, discuss what patients may derive the most benefit and practical technical components to optimize IABP therapy.


After completing the webinar, the participant should be able to::


• Assess the physiologic effects of Intra-aortic balloon counterpulsation (IABP) therapy

• Understand the clinical utility of IAB use

• Describe the factors that effect IAB catheter performance and benefits of larger-capacity IAB catheters


Speaker:



Atman P. Shah 

Associate Professor of Medicine 

Clinical Director, Section of Cardiology 

Co-Director, Cardiac Catheterization Laboratory


Atman P. Shah, M.D., is an interventional cardiologist at the University of Chicago. Shah's research efforts focus on improving survival rates in patients who have experienced a cardiac arrest or an acute myocardial infarction (heart attack). Additionally, he studies new therapies that can help save heart muscle during a heart attack. Shah is the primary investigator on a number of large multicenter clinical trials investigating novel medications and devices designed to improve the quality of life in patients with coronary artery and structural heart disease. Shah has authored six book chapters and more than 50 abstracts and publications. A dedicated educator, he trains medical students, residents and fellows. He is the recipient of several honors and awards for clinical service, leadership and teaching.


About Maquet Medical Systems

Since 1838, the Maquet brand has been synonymous with high-quality products for patient-focused care. Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Cardiovascular specialties include intra-aortic balloon counterpulsation therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation. Maquet continuously strives to develop innovative technologies that enhance clinical expertise and improve healthcare economics, while also enabling medical professionals to achieve the best possible outcomes for all patients.


For more information please visit www.maquet.com



Register for the on demand webinar


Related Content

Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.
Technology | Vascular Closure Devices| December 14, 2017
Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt...
FDA Approves New Indication for NuMed CP Stent System
Technology | Stents Bare Metal| December 14, 2017
The U.S. Food and Drug Administration (FDA) announced clearance for NuMed’s Cheatham Platinum (CP) Stent System, which...
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging| December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Philips Azurion Platform Improves Clinical Workflow and Staff Experience Benefits
News | Angiography| December 04, 2017
Philips recently announced the results of a comprehensive, independent, two-year study demonstrating the clinical...
Overlay Init